WebNov 18, 2011 · DPOC-4088 is an orally active, potent, rapidly binding, reversible direct thrombin inhibitor (DTI) being developed as a once-a-day alternative to warfarin for primary prevention of venous thromboembolism. Objectives: WebJul 28, 2024 · LONDON, July 28, 2024 /PRNewswire/ --. Antithrombotic Drugs Market 2024-2027: Anticoagulants, Antiplatelets, Fibrinolytics The revenue of the antithrombotic drugs …
Diakron Pharmaceuticals Company Profile: Acquisition & Investors PitchBook
WebIts pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins … WebJul 28, 2024 · Diakron Pharmaceuticals Dr. Reddy's Laboratories DuPont Merck Eisai Eli Lilly EMS Endo Laboratories ESP Pharma Eurofarma Fournier Pharma Gate Pharmaceuticals Genentech GlaxoSmithKline (GSK)... csulb international students
Antithrombotic Drugs Market 2024-2027
WebdigitGaps report on Diakron Pharmaceuticals Inc delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses … WebSep 6, 2016 · Diakron Pharmaceutical Inc.; Orchid DP-4088 Phase I Thrombosis Chemicals & Pharmaceuticals Ltd. (small molecule) Momenta Pharmaceuticals Inc. M-enoxaparin Marketed DVT; ACS SIX:NOVN) (Continues on p. 3) SciBX: Science–Business eXchange Copyright © 2014 Nature Publishing Group 2 analysis targets & mechanisMS … WebAug 18, 2008 · Diakron received an exclusive, worldwide license from Merck to develop and market DP-4088 for any indication. Diakron will develop the compound as an … csulb internship fair